Immunocore Holdings Plc ((IMCR)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Immunocore Holdings Plc is conducting a Phase 2/3 study titled ‘Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM)’. The study aims to assess the efficacy and safety of tebentafusp-based treatments compared to investigator’s choice in patients with advanced non-ocular melanoma. This research is significant as it explores new treatment avenues for a challenging cancer type.
Intervention/Treatment: The study tests three interventions: Tebentafusp monotherapy, Tebentafusp combined with Pembrolizumab, and an investigator’s choice of therapy. Tebentafusp is a soluble gp100-specific T cell receptor with anti-CD3 scFV, designed to target melanoma cells.
Study Design: This is a randomized, parallel-assignment study with no masking, focusing on treatment as the primary purpose. Participants are allocated to one of the three treatment arms to evaluate the effectiveness of each intervention.
Study Timeline: The study began on August 26, 2022, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
Market Implications: The study’s progress could positively influence Immunocore’s stock performance by demonstrating potential breakthroughs in melanoma treatment. Investors may view this as a promising development, enhancing the company’s competitive position in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.